CN115073493B - 雌激素受体调节剂 - Google Patents

雌激素受体调节剂 Download PDF

Info

Publication number
CN115073493B
CN115073493B CN202210249231.0A CN202210249231A CN115073493B CN 115073493 B CN115073493 B CN 115073493B CN 202210249231 A CN202210249231 A CN 202210249231A CN 115073493 B CN115073493 B CN 115073493B
Authority
CN
China
Prior art keywords
methyl
isoquinolin
trifluoroethyl
tetrahydrooxazolo
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210249231.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115073493A (zh
Inventor
朱程刚
杨铉
张朝春
J·J·泰利
陈超乐
包丽茗
闵祥燕
徐良亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Forward Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Forward Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Forward Pharmaceuticals Co Ltd filed Critical Shenzhen Forward Pharmaceuticals Co Ltd
Priority to CN202510027136.XA priority Critical patent/CN119930646A/zh
Publication of CN115073493A publication Critical patent/CN115073493A/zh
Application granted granted Critical
Publication of CN115073493B publication Critical patent/CN115073493B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN202210249231.0A 2021-03-15 2022-03-14 雌激素受体调节剂 Active CN115073493B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510027136.XA CN119930646A (zh) 2021-03-15 2022-03-14 雌激素受体调节剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021102778493 2021-03-15
CN202110277849 2021-03-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510027136.XA Division CN119930646A (zh) 2021-03-15 2022-03-14 雌激素受体调节剂

Publications (2)

Publication Number Publication Date
CN115073493A CN115073493A (zh) 2022-09-20
CN115073493B true CN115073493B (zh) 2024-12-10

Family

ID=83246765

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210249231.0A Active CN115073493B (zh) 2021-03-15 2022-03-14 雌激素受体调节剂
CN202510027136.XA Pending CN119930646A (zh) 2021-03-15 2022-03-14 雌激素受体调节剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510027136.XA Pending CN119930646A (zh) 2021-03-15 2022-03-14 雌激素受体调节剂

Country Status (7)

Country Link
US (1) US20240217988A1 (https=)
EP (1) EP4310079A4 (https=)
JP (2) JP7605536B2 (https=)
KR (1) KR20230157439A (https=)
CN (2) CN115073493B (https=)
AU (1) AU2022240650B2 (https=)
WO (1) WO2022194096A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7605536B2 (ja) * 2021-03-15 2024-12-24 深▲せん▼福沃薬業有限公司 エストロゲン受容体モジュレーター

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109219604A (zh) * 2016-04-08 2019-01-15 豪夫迈·罗氏有限公司 四氢异喹啉雌激素受体调节剂及其用途
CN107406457B (zh) * 2015-06-16 2019-02-01 江苏恒瑞医药股份有限公司 哌啶类衍生物、其制备方法及其在医药上的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
WO2012142029A2 (en) * 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
CN104910137B (zh) * 2014-03-10 2017-04-19 山东轩竹医药科技有限公司 Cdk激酶抑制剂
US10125135B2 (en) * 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
WO2018138739A1 (en) * 2017-01-27 2018-08-02 Sun Pharma Advanced Research Company Limited Novel antiestrogenic heterocyclic compounds
WO2019192533A1 (zh) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
TW202003495A (zh) * 2018-05-23 2020-01-16 大陸商江蘇恒瑞醫藥股份有限公司 苯並哌啶或雜芳基並哌啶類衍生物、其製備方法及其在醫藥上的應用
JP7605536B2 (ja) * 2021-03-15 2024-12-24 深▲せん▼福沃薬業有限公司 エストロゲン受容体モジュレーター

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406457B (zh) * 2015-06-16 2019-02-01 江苏恒瑞医药股份有限公司 哌啶类衍生物、其制备方法及其在医药上的应用
CN109219604A (zh) * 2016-04-08 2019-01-15 豪夫迈·罗氏有限公司 四氢异喹啉雌激素受体调节剂及其用途

Also Published As

Publication number Publication date
EP4310079A1 (en) 2024-01-24
AU2022240650A1 (en) 2023-10-19
US20240217988A1 (en) 2024-07-04
EP4310079A4 (en) 2024-10-30
JP7605536B2 (ja) 2024-12-24
KR20230157439A (ko) 2023-11-16
WO2022194096A1 (zh) 2022-09-22
CN115073493A (zh) 2022-09-20
JP2024511044A (ja) 2024-03-12
JP2025023300A (ja) 2025-02-14
AU2022240650B2 (en) 2025-01-30
CN119930646A (zh) 2025-05-06

Similar Documents

Publication Publication Date Title
KR102614939B1 (ko) 피리미딘-융합고리 화합물 및 그의 제조방법과 용도
CN112239473B (zh) 作为hpk1抑制剂的三环化合物的制备方法
ES2902050T3 (es) Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1
KR102384139B1 (ko) 탈유비퀴틴화 효소(dub) 억제제로서 스피로-축합된 피롤리딘 유도체
RU2676259C2 (ru) Ингибиторы днк-пк
CN115448923B (zh) 嘧啶并环化合物及其制备方法和应用
CN116888108B (zh) 新型egfr降解剂
JP2022503942A (ja) イソインドリン化合物、その調製方法、医薬組成物および使用
CN116981675A (zh) 通过布鲁顿氏酪氨酸激酶（btk）抑制剂与e3连接酶配体的缀合降解btk和使用方法
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
JP7584623B2 (ja) キナーゼ阻害活性を有する化合物
CN110655520A (zh) 嘧啶并环化合物及其制备方法和应用
CN115073493B (zh) 雌激素受体调节剂
WO2010092342A1 (en) Organosilicon compounds and their use as the modulators of the trpv1 receptor
KR20250004826A (ko) 암 치료에서의 egfr 저해제
TW202330537A (zh) Wee1抑制劑及其製備和用途
CN116783188A (zh) 一种二氢异喹啉酮衍生物及其应用
CN114761399B (zh) 作为布鲁顿酪氨酸激酶抑制剂的咪唑甲酰胺衍生物
HK40106742A (en) Estrogen receptor antagonist
WO2026039844A1 (en) Stat6 degraders and uses thereof
EP3345909B1 (en) Tetrahydrooxepinopyridine compound
CN121263412A (zh) 用于雄激素受体依赖性疾病的苯并(杂)环烷基化合物
WO2023220247A1 (en) Lrrk2 inhibitors
EP4592286A1 (en) Macrocyclic nitrogen-containing crown ether compound and use thereof as protein kinase inhibitor
CN121226391A (zh) 一种杂环化合物及其组合物和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant